Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium (177Lu) rhPSMA-10.1 in metastatic castration-resistant prostate cancer
2024-511537-35-00Phase 2Authorised
- Sponsor
- Blue Earth Therapeutics
- Start
- Jul 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of lutetium (177Lu) rhPSMA-10.1 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Blue Earth Therapeutics. Primary endpoints: Incidence of dose-limiting toxicities (DLTs) during the DLT observation period (Phase 1), Frequency and nature of treatment-emergent adverse events (TEAEs) (Phase 1) and 1 more. Planned start Jul 2024; status: authorised.
02
Drugs
lutetium (177Lu) rhPSMA-10.1
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-511537-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511537-35-00.